Omega-3 supplements in gout

Not Applicable

Completed

• Conditions: Gout; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12617000539336
• Lead Sponsor: niversity of Otago, Christchurch

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-04-13
• Study Completion: 2019-06-28
• Last Update Posted: 16 March 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Age over 18 years
Gout according to the 2015 ACR/EULAR criteria
Ability to give informed consent
Ability to communicate via telephone
Stable dose of allopurinol for at least one month
Serum urate >0.36mmol/l at screening

Exclusion Criteria

Previous intolerance or allergy with omega-3 fatty acid supplementation
Unstable co-morbid health conditions
Unable to comply with study procedures
Already taking at least 2gm daily of omega-3 supplements
Not willing to remain off omega-3 supplements if randomised to control arm
Allergy to fish or shell fish
Implantable defibrillator
Current use of warfarin or dabigatrin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary efficacy outcome measure will be change in serum urate [Month 6]

Secondary Outcome Measures

Name	Time	Method
Change in weight between months 0 and 6 as measured on scales<br>[six months];Mean number of self reported gout flares[Six months];Percentage of participants with self reported gout flare[At each month for six months from study entry];Need for medication to treat gout flares as reported by patient and review of medical records[At six months];Cessation of fish oil due to adverse effects such as nausea, heartburn. Adverse effects will be assessed by patient questionnaire designed for this study[Six months];Requirement for change in urate lowering therapy medication use as reported by patient and review of medical records[Six months];Time to first gout flare during the study period[Gout flares reported by patient captured at time it occurs during the six month study period];Change in plasma oxypurinol concentration[Assessed at six months by blood test]